Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 1Glioblastoma 1Carcinoma, Medullary 1

Interventions

cabozantinib 3selpercatinib 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1sargramostim 1rovalpituzumab tesirine 1pentetreotide 1lutetium Lu 177 dotatate 1lenvatinib 1cixutumumab 1aldesleukin 1Vinorelbine 1Trastuzumab 1Tamoxifen 1Sirolimus 1Semaxinib 1Salts 1Restraint, Physical 1Radiotherapy 1Paclitaxel 1Octreotide 1Magnetic Resonance Spectroscopy 1Gefitinib 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × rovalpituzumab tesirine × CNS × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡